MétaCan
Menu
← all works

Spectrum and prevalence of genetic predisposition in medulloblastoma: a retrospective genetic study and prospective validation in a clinical trial cohort

2018· article· en· 394 citations· W2799574682 on OpenAlex· 10.1016/s1470-2045(18)30242-0

Why is this work in the frame?

A frame that forgets how it found something cannot be audited. These are the routes that admitted this work.

Canadian affiliationAn author listed a Canadian institution. This is the only route the usual frame has.
Canadian funderA Canadian agency funded it. The work may carry no Canadian affiliation at all.
About CanadaIts subject is Canada, wherever its authors sit.

Full frame distilled prediction

Learned from the 10,348 direct Codex labels and 10,348 direct Gemma labels. Candidate is the union of thresholded teacher heads; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels or direct frontier model labels.

Candidate categories
none
Consensus categories
none
Domain
Candidate signal: noneConsensus signal: none
Study design
Candidate signal: ObservationalConsensus signal: Observational
Genre
Candidate signal: EmpiricalConsensus signal: Empirical
Teacher disagreement score
0.055
Threshold uncertainty score
0.284
Validation status
machine_predicted_unvalidated · codex-gemma-dda1882f352a

Codex and Gemma teacher scores by category

CategoryCodexGemma
Metaresearch0.0010.000
Meta-epidemiology (narrow)0.0000.000
Meta-epidemiology (broad)0.0010.000
Bibliometrics0.0000.000
Science and technology studies0.0000.000
Scholarly communication0.0000.000
Open science0.0000.000
Research integrity0.0000.000
Insufficient payload (model declined to judge)0.0000.000

Machine scores (provisional)

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Opus teacher head0.036
GPT teacher head0.377
Teacher spread
0.341 · how far apart the two teachers sit on this one work
Validation status
score_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Abstract

BACKGROUND: Medulloblastoma is associated with rare hereditary cancer predisposition syndromes; however, consensus medulloblastoma predisposition genes have not been defined and screening guidelines for genetic counselling and testing for paediatric patients are not available. We aimed to assess and define these genes to provide evidence for future screening guidelines. METHODS: ). Medulloblastoma predisposition genes were predicted on the basis of rare variant burden tests against controls without a cancer diagnosis from the Exome Aggregation Consortium (ExAC). Previously defined somatic mutational signatures were used to further classify medulloblastoma genomes into two groups, a clock-like group (signatures 1 and 5) and a homologous recombination repair deficiency-like group (signatures 3 and 8), and chromothripsis was investigated using previously established criteria. Progression-free survival and overall survival were modelled for patients with a genetic predisposition to medulloblastoma. FINDINGS: molecular subgroups and were associated with mutational signatures typical of homologous recombination repair deficiency. In patients with a genetic predisposition to medulloblastoma, 5-year progression-free survival was 52% (95% CI 40-69) and 5-year overall survival was 65% (95% CI 52-81); these survival estimates differed significantly across patients with germline mutations in different medulloblastoma predisposition genes. INTERPRETATION: because these patients have the highest prevalence of damaging germline mutations in known cancer predisposition genes. We propose criteria for routine genetic screening for patients with medulloblastoma based on clinical and molecular tumour characteristics. FUNDING: German Cancer Aid; German Federal Ministry of Education and Research; German Childhood Cancer Foundation (Deutsche Kinderkrebsstiftung); European Research Council; National Institutes of Health; Canadian Institutes for Health Research; German Cancer Research Center; St Jude Comprehensive Cancer Center; American Lebanese Syrian Associated Charities; Swiss National Science Foundation; European Molecular Biology Organization; Cancer Research UK; Hertie Foundation; Alexander and Margaret Stewart Trust; V Foundation for Cancer Research; Sontag Foundation; Musicians Against Childhood Cancer; BC Cancer Foundation; Swedish Council for Health, Working Life and Welfare; Swedish Research Council; Swedish Cancer Society; the Swedish Radiation Protection Authority; Danish Strategic Research Council; Swiss Federal Office of Public Health; Swiss Research Foundation on Mobile Communication; Masaryk University; Ministry of Health of the Czech Republic; Research Council of Norway; Genome Canada; Genome BC; Terry Fox Research Institute; Ontario Institute for Cancer Research; Pediatric Oncology Group of Ontario; The Family of Kathleen Lorette and the Clark H Smith Brain Tumour Centre; Montreal Children's Hospital Foundation; The Hospital for Sick Children: Sonia and Arthur Labatt Brain Tumour Research Centre, Chief of Research Fund, Cancer Genetics Program, Garron Family Cancer Centre, MDT's Garron Family Endowment; BC Childhood Cancer Parents Association; Cure Search Foundation; Pediatric Brain Tumor Foundation; Brainchild; and the Government of Ontario.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

The record

Venue
The Lancet Oncology
Topic
Glioma Diagnosis and Treatment
Field
Medicine
Canadian institutions
Canada's Michael Smith Genome Sciences CentreBC Cancer AgencyUniversity of CalgaryMcGill UniversityUniversity of TorontoToronto General HospitalUniversity Health NetworkHospital for Sick Children
Funders
National Heart, Lung, and Blood InstituteStrategic Research CouncilCanadian Institutes of Health ResearchBrain Tumour ResearchNational Cancer InstituteFondation de l'Hôpital de Montréal pour enfantsBC Cancer FoundationLékařská fakulta, Masarykova univerzitaEunice Kennedy Shriver National Institute of Child Health and Human DevelopmentMasarykova UniverzitaNationales Centrum für Tumorerkrankungen HeidelbergGöteborgs UniversitetUniversitetet i OsloKarolinska InstitutetTerry Fox Research InstituteCancerfondenUniversität ZürichBundesministerium für Bildung und ForschungNorges ForskningsrådSemmelweis EgyetemBundesamt für GesundheitPediatric Brain Tumor FoundationDeutsche KrebshilfeSchweizerischer Nationalfonds zur Förderung der Wissenschaftlichen ForschungBroad InstituteForskningsrådet om Hälsa, Arbetsliv och VälfärdUniversidad Nacional Autónoma de MéxicoPediatric Oncology Group of OntarioFH FoundationInstituto Mexicano del Seguro SocialColorado State UniversityBarncancerfondenOntario Institute for Cancer ResearchUniversity of MiamiEuropean Molecular Biology OrganizationUniversity of BernMinisterstvo Zdravotnictví Ceské RepublikyRockefeller UniversityMassachusetts Institute of TechnologyUniversität BaselNational Institutes of HealthChildren's Hospital FoundationJohn D. and Catherine T. MacArthur FoundationGenome CanadaGarron Family Cancer CentreEuropean CommissionSontag FoundationHospital for Sick ChildrenGenome British ColumbiaStrategiske ForskningsrådCancer Research UKWorld Health OrganizationDeutsche KinderkrebsstiftungUniversity of ChicagoUniversity of CaliforniaVetenskapsrådetEuropean Research CouncilV Foundation for Cancer ResearchGovernment of OntarioAlexander and Margaret Stewart TrustDeutsches Krebsforschungszentrum
Keywords
MedulloblastomaGenetic predispositionRetrospective cohort studyMedicineProspective cohort studyCohortClinical trialOncologyPediatricsInternal medicinePathology
Has abstract in OpenAlex
yes